Onconetix Inc
ONCO
View Detailed Chart
1.520USD
-0.060-3.80%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
2.37MMarket Cap
0.00P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-3.80%
5 Days
-20.42%
1 Month
-35.32%
6 Months
-63.11%
Year to Date
-97.16%
1 Year
-94.74%
View Detailed Chart
TradingKey Stock Score of Onconetix Inc
Currency: USD Updated: 2025-12-24Key Insights
Onconetix Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 123/158 in the Pharmaceuticals industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend down.The company has shown very weak stock market performance over the past month, in line with its fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Onconetix Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
0
analysts
--
Current Rating
0.000
Target Price
0.00%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Onconetix Inc Highlights
StrengthsRisks
Onconetix, Inc. is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men’s health and oncology. The Company owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (PSA) test.
Growing
The company is in a growing phase, with the latest annual income totaling USD 2.52M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 2.52M.
Overvalued
The company’s latest PE is 0.00, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 22.38K shares, increasing 43.25% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Onconetix Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Onconetix Inc Info
Onconetix, Inc. is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men’s health and oncology. The Company owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (PSA) test.
Ticker SymbolONCO
CompanyOnconetix Inc
CEOFedasz (Karina M)
Websitehttps://www.onconetix.com/
FAQs
What is the current price of Onconetix Inc (ONCO)?
The current price of Onconetix Inc (ONCO) is 1.520.
What is the symbol of Onconetix Inc?
The ticker symbol of Onconetix Inc is ONCO.
What is the 52-week high of Onconetix Inc?
The 52-week high of Onconetix Inc is 179.350.
What is the 52-week low of Onconetix Inc?
The 52-week low of Onconetix Inc is 1.535.
What is the market capitalization of Onconetix Inc?
The market capitalization of Onconetix Inc is 2.37M.
What is the net income of Onconetix Inc?
The net income of Onconetix Inc is -58.90M.
Is Onconetix Inc (ONCO) currently rated as Buy, Hold, or Sell?
According to analysts, Onconetix Inc (ONCO) has an overall rating of --, with a price target of --.
What is the Earnings Per Share (EPS TTM) of Onconetix Inc (ONCO)?
The Earnings Per Share (EPS TTM) of Onconetix Inc (ONCO) is 1229.567.
Related Instruments
+0.41%
+0.94%
+0.51%
+0.34%
-0.17%
+1.42%
+0.75%
+1.80%
+0.38%
+0.66%
+0.08%
+0.82%
+0.81%
+0.08%
+0.23%
-0.05%
-0.19%
0.00%
+1.54%
+0.50%
